 | Up a level |
Jump to: 2022
Number of items: 1.
2022
Wolf, J., Helland, A., Oh, I-J, Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V and Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029